argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
argenx (Nasdaq: ARGX) announced an upcoming R&D webinar focusing on their ARGX-119 program, scheduled for September 16, 2025, at 2:00pm ET. The event, titled "R&D Spotlight | Pioneering MuSK Biology with ARGX-119," marks the first in a mini-series highlighting the company's pipeline and R&D strategy.
The webinar will feature argenx management, scientific leadership, and key opinion leaders discussing the MuSK agonist program and its potential applications in treating neuromuscular diseases, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). The presentation will be accessible through the company's investor relations website.
argenx (Nasdaq: ARGX) ha annunciato un webinar R&D dedicato al suo programma ARGX-119, in programma per il 16 settembre 2025 alle 14:00 ET. L'evento, intitolato "R&D Spotlight | Pioneering MuSK Biology with ARGX-119", 猫 il primo di una mini-serie che mette in luce il pipeline e la strategia di ricerca e sviluppo dell'azienda.
Al webinar parteciperanno il management di argenx, i responsabili scientifici e opinion leader che discuteranno il programma agonista MuSK e le sue possibili applicazioni nel trattamento delle malattie neuromuscolari, comprese le congenite sindromi miasteniche (CMS), la sclerosi laterale amiotrofica (SLA) e l'atrofia muscolare spinale (SMA). La presentazione sar脿 disponibile tramite il sito web per gli investitori della societ脿.
argenx (Nasdaq: ARGX) anunci贸 un webinar de I+D centrado en su programa ARGX-119, programado para el 16 de septiembre de 2025 a las 2:00 p.m. ET. El evento, titulado "R&D Spotlight | Pioneering MuSK Biology with ARGX-119", es el primero de una miniserie que destaca la cartera y la estrategia de I+D de la compa帽铆a.
En el webinar participar谩n la direcci贸n de argenx, l铆deres cient铆ficos y expertos clave que abordar谩n el programa agonista de MuSK y sus posibles aplicaciones en el tratamiento de enfermedades neuromusculares, incluidas las s铆ndromes miast茅nicas cong茅nitas (CMS), la esclerosis lateral amiotr贸fica (ELA) y la atrofia muscular espinal (AME). La presentaci贸n estar谩 disponible a trav茅s del sitio web de relaciones con inversores de la compa帽铆a.
argenx (Nasdaq: ARGX)电� ARGX-119 頂勲攴鸽灗鞚� 欤检牅搿� 頃� 鞐瓣惮臧滊皽(R&D) 鞗箘雮橂ゼ 2025雲� 9鞗� 16鞚� 鞓ろ泟 2鞁�(ET)鞐� 臧滌禍頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. "R&D Spotlight | Pioneering MuSK Biology with ARGX-119"霛嫉鐢 鞝滊鞚� 鞚措矆 頄夓偓电� 須岇偓 韺岇澊頂勲澕鞚戈臣 R&D 鞝勲灥鞚� 臁半獏頃樀鐢 氙鸽媹 鞁滊Μ歃堨潣 觳� 氩堨Ц鞛呺媹雼�.
鞗箘雮橃棎电� argenx 瓴届榿歆�, 瓿柬暀 毂呾瀯鞛� 氚� 欤检殧 鞚橁铂 毽崝霌れ澊 彀胳劃頃� MuSK 鞛戩毄鞝� 頂勲攴鸽灗瓿� 靹犾矞靹� 欷戩攴茧霠レ(CMS), 攴检渼於曥劚 旄§偔瓴巾檾歃�(ALS), 觳欖垬靹� 攴检渼於曥(SMA) 霌� 鞁犼步攴检頇� 旃橂鞐� 雽�頃� 鞛犾灛鞝� 鞝侅毄鞚� 雲检潣頃╇媹雼�. 氚滍憸 鞛愲电� 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
argenx (Nasdaq: ARGX) a annonc茅 un prochain webinaire R&D ax茅 sur son programme ARGX-119, pr茅vu le 16 septembre 2025 脿 14h00 ET. L'茅v茅nement, intitul茅 芦 R&D Spotlight | Pioneering MuSK Biology with ARGX-119 禄, est le premier d'une mini-s茅rie mettant en avant le pipeline et la strat茅gie R&D de la soci茅t茅.
Le webinaire r茅unira la direction d'argenx, les responsables scientifiques et des leaders d'opinion qui discuteront du programme agoniste MuSK et de ses applications potentielles dans le traitement des maladies neuromusculaires, y compris les syndromes myasth茅niques cong茅nitaux (SMC), la scl茅rose lat茅rale amyotrophique (SLA) et l'amyotrophie spinale (AMS). La pr茅sentation sera accessible via le site web des relations investisseurs de la soci茅t茅.
argenx (Nasdaq: ARGX) gab ein bevorstehendes F&E-Webinar zu seinem ARGX-119-Programm bekannt, das f眉r den 16. September 2025 um 14:00 Uhr ET angesetzt ist. Die Veranstaltung mit dem Titel "R&D Spotlight | Pioneering MuSK Biology with ARGX-119" ist die erste einer Mini-Serie, die die Pipeline und die F&E-Strategie des Unternehmens hervorhebt.
Am Webinar werden das Management von argenx, die wissenschaftliche Leitung und Meinungsf眉hrer teilnehmen, um das MuSK-Agonistenprogramm und dessen potenzielle Anwendungen bei der Behandlung neuromuskul盲rer Erkrankungen zu diskutieren, darunter kongenitale myasthene Syndrome (CMS), amyotrophe Lateralsklerose (ALS) und spinale Muskelatrophie (SMA). Die Pr盲sentation wird 眉ber die Investor-Relations-Website des Unternehmens zug盲nglich sein.
- None.
- None.
August 19, 2025
Amsterdam, the Netherlands 鈥� argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled 鈥淩&D Spotlight | Pioneering MuSK Biology with ARGX-119鈥� on Tuesday, September 16, 2025, at 2:00pm ET.
The webinar will be the first of a 鈥榤ini鈥� series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by key opinion leaders, who will discuss the development of the MuSK agonist program, ARGX-119, and its potential to treat neuromuscular diseases, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
A webcast of the event can be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit聽聽and follow us on聽,听,听, and聽.
Contacts
Media:
Colin McBean
Investors:
Alexandra Roy
FAQ
When is argenx (ARGX) hosting its R&D webinar on ARGX-119?
What diseases will ARGX-119 target according to argenx's webinar announcement?
How can investors access argenx's ARGX-119 R&D webinar?
What is the focus of argenx's ARGX-119 program?
